This analysis looks at two Nasdaq-listed companies operating in different segments of the healthcare and life-sciences space. DRTS is Alpha Tau Medical, focused on a proprietary alpha-radiation therapy for oncology, while ORMP is Oramed Pharmaceuticals, which has shifted from drug-delivery development into a diversified operating and investment firm. Because ORMP maintains a substantial position in Alpha Tau Medical, the two tickers are more closely connected than they might appear at first. Growth-oriented investors may see appeal in DRTS's clinical catalysts, while those seeking value or income could consider ORMP's asset-backed balance sheet and dividend. Comparing their performance and positioning can clarify which profile fits a particular strategy.
Alpha Tau Medical (DRTS) is advancing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a method that places radioactive seeds into solid tumors for targeted alpha radiation. The company remains pre-revenue and posted a net loss in its latest filings, supported by roughly $105 million in cash for ongoing development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market movement has centered on clinical updates. Interim results from the U.S. REGAIN trial in recurrent glioblastoma indicated that all evaluable patients achieved an objective response, with five of six showing a complete response and no unexpected serious adverse events. These findings built on prior positive signals and a commercial collaboration with Tolmar for prostate cancer. The share price has climbed sharply over the past year, prompting analyst upgrades and higher price targets that now reflect a "Strong Buy" consensus. This reflects optimism about the platform's reach across solid-tumor indications, though future trial outcomes and regulatory steps remain key.
Oramed Pharmaceuticals (ORMP) has repositioned as a diversified operating company. After moving its oral drug-delivery platform to Lifeward, Oramed now concentrates on building and managing a strategic biomedical investment portfolio. Its largest holding is a stake in Alpha Tau Medical (DRTS) that has grown substantially, along with a secured loan to Scilex Holding that has been largely repaid.
Recent activity has been more restrained. Addition to the Russell 2000 and Russell 3000 indexes, a stronger balance sheet, and a dividend have added stability, with earnings influenced more by investment gains than operating revenue. ORMP's share price has shown less consistent upward movement than DRTS, and its smaller market capitalization along with lower average trading volume create a distinct liquidity profile. Sentiment here ties to the performance of underlying holdings and capital deployment pace rather than a single product pipeline.
The companies differ markedly in structure. DRTS is a single-platform, pre-revenue oncology developer whose value depends on clinical execution, regulatory approvals, and eventual commercialization. ORMP operates as a portfolio-style holding company whose value rests on investment appreciation, including its Alpha Tau stake. This creates an unusual linkage where ORMP's performance is partly tied to DRTS's results.
DRTS provides concentrated exposure to a differentiated cancer-therapy platform with multiple U.S. trials underway and upcoming readouts. ORMP offers diversified, asset-backed exposure plus a dividend and solid cash position, though with less direct influence over its value drivers. Risks also contrast: DRTS faces typical pre-revenue biotech challenges around clinical, regulatory, and financing matters, while ORMP contends with concentration in its largest holdings and lower trading liquidity. On momentum, DRTS has shown stronger recent relative performance backed by favorable analyst views, whereas ORMP's price action has been steadier but less directional.
Considering factors such as trend consistency, relative momentum, analyst sentiment, and near-term catalysts, the edge appears to lie with DRTS over ORMP in the current setting. DRTS has posted a clearer upward trend supported by repeated positive clinical data and a "Strong Buy" consensus, while ORMP's price behavior has been less directional and its value is partly linked to the same underlying asset. This remains a probabilistic view rather than a firm prediction, and the tilt toward DRTS does not remove the meaningful risks in either name.
I've found Tickeron’s AI Trading Bots useful when evaluating names like these, as the platform offers a range of strategies with tracked performance histories that can complement traditional analysis. Checking the curated selection of bots aligned with current conditions provides an additional data-driven perspective on momentum and positioning across healthcare stocks.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for ORMP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 184 cases the stock moved lower. This puts the odds of a downward move at 82%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for ORMP turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.586). P/E Ratio (0.910) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in pharmaceutical preparations
Industry Biotechnology